A call to action on World Kidney Day, 8 March 2007

Kidney International

Volumn 71, Issue 5, 2007, Pages 369-370

  Couser, William G ^a,c   Shah, Sudhir ^b   Kopple, Joel ^b   Beerkens, Paul ^b   Wilson, Anne ^b   Feehally, John ^b   Reiser, Thomas ^b   Riella, Miguel ^b  

^a International Society of Nephrology   (United States)

^b International Federation of Kidney Foundations ^*

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; EDITORIAL; GLOMERULUS FILTRATION RATE; HEALTH PROGRAM; HUMAN; KIDNEY; KIDNEY FAILURE; PRIORITY JOURNAL; PUBLIC HEALTH;

HUMANS; KIDNEY; KIDNEY DISEASES; WORLD HEALTH;

EID: 33847195702     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002144     Document Type: Editorial

References (19)

1. Coresh J, Astor BC, Greene T et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41: 1-12.
2. Gansevoort RT, van der Heij B, Stegeman CA et al. Trends in the incidence of treated end-stage renal failure in the Netherlands: hope for the future? Kidney Int Suppl 2004; 7-10.
3. Uhlig K, Macleod A, Craig J et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 70: 2058-2065.
4. El Nahas ME. The global challenge of chronic kidney disease (Nephrology Forum). Kidney Int 2005; 68: 2918-2929.
5. Hallan SI, Coresh J, Astor BC et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 2006; 17: 2275-2284.
6. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalisation. N Engl J Med 2004; 351: 1296-1305.
7. Weiner DE, Tabatabai S, Tighiouart H et al. Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. Am J Kidney Dis 2006; 48: 392-401.
8. Keith D, Nicholls G, Guillion C et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organisation. Arch Intern Med 2004; 164: 659-663.
9. Mann JFE, Gerstein HC, Pogue J et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2006; 134: 629-636.
10. Solomon SD, Rice MM, Jablonski KA et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation 2006; 114: 26-23.
11. Asselbergs FW, Diercks GF, Hillege HL et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110: 2809-2816.
12. Ibsen H, Wachtell K, Olsen MH et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE Study. Kidney Int Suppl 2004; S56-S58.
13. Yuyun MF, Adler AI, Wareham NJ. What is the evidence that microalbuminuria is a predictor of cardiovascular disease events? Curr Opin Nephrol Hypertens 2006; 14: 271-276.
14. World Health Organization. Preventing Chronic Diseases: a Vital Investment. World Health Organization: Geneva, 2005, pp 1-182.
15. Codreanu I, Perico N, Sharma SK et al. Prevention programmes of progressive renal disease in developing nations. Nephrology 2006; 11: 321-328.
16. Perico N, Plata R, Anabaya A et al. Strategies for national health care systems in emerging countries: the case of screening and prevention of renal disease progression in Bolivia. Kidney Int Suppl 2005; S87-S94.
17. Mani MK. Nephrologists sans frontières: preventing chronic kidney disease on a shoestring. Kidney Int 2006; 70: 821-823.
18. Atthobari J, Asselbergs FW, Boersma C et al. Costeffectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: a pharmacoeconomic analysis linked to the PREVEND and PREVEND-IT study. Clin Ther 2006; 28: 432-444.
19. Levey AS, Andreoli SP, DuBose T et al. Chronic kidney disease: common, harmful and treatable - World Kidney Day 2007. J Am Soc Nephrol 2007 (e-pub 1/17/2007).